Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding
This article was originally published in The Pink Sheet Daily
Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.
You may also be interested in...
Encouraging results from some early 2013 offerings have led to four new filings in April. If the pattern holds, this year could be a better year for new listings than 2012.
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.
Biopharmaceutical company financings more than doubled to $2.7 billion from Q3. There were 23 acquisitions bringing in a total of $17.7 billion. And in alliances there was a focus on biosimilars, oncology and neurology deals, and unique partnerships with clear paths to exits.